

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001384243
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Kiniksa Pharmaceuticals International, plc
SEC File Number 001-38492
Address of Issuer 105 PICCADILLY, SECOND FLOOR
LONDON
UNITED KINGDOM
W1J 7NJ
Phone 7814319100
Name of Person for Whose Account the Securities are To Be Sold Quart Barry D

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	1000000.00	45900637	04/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this Acquired	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------------------	-----------------------------------	------------------	---------------------	-------------------------------	-----------------	---------------------

**a
Gift?**

Class A ordinary shares	04/06/2026	Employee Stock Option Exercise - see remarks	Kiniksa Pharmaceuticals, Ltd.	☐	20000	04/06/2026	Broker Payment for Cashless Exercise
----------------------------	------------	--	-------------------------------------	---	-------	------------	--

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/02/2026	830	37354.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/03/2026	12528	567136.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/04/2026	2602	117138.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/10/2026	110	4950.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/12/2026	2690	121050.00

144: Remarks and Signature

Remarks	The shares on this filing may be sold over various dates.
Date of Notice	04/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/11/2025

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature Barry D Quart

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)